From: Impact of contrast-enhanced CT in the dosimetry of SBRT for liver metastases treated with MR-Linac
Patients | |
Number | 21 |
Years, median (range) | 52.5 (29–73) |
Weight (kg), median (range) | 61.0 (36–84) |
Female - no. (%) | 12 (57.1%) |
Male - no. (%) | 9 (42.9%) |
aPTV – no. (%) | |
4 cc < Volume < 14 cc | 7 (33.3%) |
14 cc < Volume < 24 cc | 5 (23.8%) |
24 cc < Volume < 34 cc | 3 (14.3%) |
34 cc < Volume < 54 cc | 6 (28.6%) |
Volume(cc), median (range) | 27.9 (9.8–71.4) |
ClosestbOARs – no. (%) | |
Duodenum | 0(0%) |
Esophagus | 2 (9.5%) |
Great Vessels | 1 (4.8%) |
Heart | 4 (19.0%) |
Liver -cGTV | 2 (9.5%) |
Spinal cord | 2 (9.5%) |
Rib | 8 (38.1%) |
Stomach | 3(14.3%) |
Small Bowel | 4(19.0%) |
Lung | 5(23.8%) |
Kidney | 1(4.8%) |